Elhendy Abdou, Schinkel Arend, Bax Jeroen J, van Domburg Ron T, Poldermans Don
Throraxcenter, University Hospital-Dijkzigt, Totterdam, The Netherlands.
J Nucl Cardiol. 2003 May-Jun;10(3):261-6. doi: 10.1016/s1071-3581(02)43219-9.
Patients with a normal stress technetium 99m sestamibi study were shown to have a favorable outcome at intermediate-term follow-up. However, long-term survival has not been studied. The aim of this study was to evaluate the incidence and predictors of mortality and cardiac events at long-term follow-up after a normal exercise stress sestamibi study. Methods and results We studied 218 patients (mean age, 53 +/- 10 years, 108 men) who had normal myocardial perfusion assessed by Tc-99m sestamibi single photon emission computed tomography at rest and during symptom-limited bicycle exercise stress test. Endpoints during a follow-up period of 7.4 +/- 1.8 years were hard cardiac events (cardiac death and nonfatal myocardial infarction) and all-cause mortality. During follow-up, 13 patients died of various causes (cardiac death in 1 patient). Ten patients had nonfatal myocardial infarction (a total of 11 hard cardiac events). By multivariate analysis, independent predictors of cardiac events were history of coronary artery disease (chi(2) = 5, P =.03) and lower exercise heart rate (chi(2) = 12, P =.001). Independent predictors of all-cause mortality were age (chi(2) = 4, P =.05) and exercise heart rate (chi(2) = 5, P =.03). The annual mortality rate was 0.6% in the first 5 years and 1.8% between the sixth and eighth years. The annual hard cardiac event rate was 0.7% in the first 5 years and 1.5% between the sixth and eighth years. Receiver operating characteristic curves identified an exercise heart rate lower than 130 beats/min as the cutoff value that separated patients with regard to their risk for mortality and hard cardiac events.
It is concluded that the annual mortality and cardiac event rate is less than 1% during 5-year follow-up after a normal exercise sestamibi study. Therefore repeated testing would not be required unless there is a change in symptoms. Follow-up should be closer in patients with a history of coronary artery disease and in those who fail to achieve an exercise heart rate of 130 beats/min or greater.
正常负荷锝99m甲氧基异丁基异腈检查的患者在中期随访中显示预后良好。然而,长期生存率尚未得到研究。本研究的目的是评估正常运动负荷甲氧基异丁基异腈检查后长期随访时的死亡率和心脏事件的发生率及预测因素。方法与结果 我们研究了218例患者(平均年龄53±10岁,男性108例),这些患者在静息和症状限制性自行车运动负荷试验期间通过锝99m甲氧基异丁基异腈单光子发射计算机断层扫描评估心肌灌注正常。在7.4±1.8年的随访期内的终点是严重心脏事件(心源性死亡和非致命性心肌梗死)和全因死亡率。随访期间,13例患者死于各种原因(1例心源性死亡)。10例患者发生非致命性心肌梗死(共11例严重心脏事件)。通过多因素分析,心脏事件的独立预测因素是冠状动脉疾病史(χ2=5,P=0.03)和较低的运动心率(χ2=12,P=0.001)。全因死亡率的独立预测因素是年龄(χ2=4,P=0.05)和运动心率(χ2=5,P=0.03)。前5年的年死亡率为0.6%,第6至8年为1.8%。前5年的年严重心脏事件发生率为0.7%,第6至8年为1.5%。受试者工作特征曲线确定运动心率低于130次/分钟为区分患者死亡风险和严重心脏事件风险的临界值。
得出结论,正常运动甲氧基异丁基异腈检查后5年随访期间的年死亡率和心脏事件发生率低于1%。因此,除非症状有变化,否则无需重复检查。对于有冠状动脉疾病史的患者以及运动心率未达到130次/分钟或更高的患者,应进行更密切的随访。